New NNT→Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study https://t.co/WmB5MoSEWH
502 followers
281 followers
RT @FrontImmunol: New Research: Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-control…
32,811 followers
New Research: Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study: Objective To address a novel lower-dose rituximab (RTX) therapy strategy based on our… #immunology h
5,321 followers